Lung Cancer

Pfizer Inc.’s phase 3 CROWN trial examining lorlatinib to treat patients with ALK-positive NSCLC met its primary end point of improving progression-free survival when compared to crizotinib.

Researchers suggested that based on their findings, increased efforts are needed to implement intervention strategies tailored to local settings to effectively decrease the global lung cancer burden and reduce health inequality.

This study created and assessed a parsimonious radiomic model that was able to identify a vulnerable subset of screen-detected lung cancers that are associated with poor outcome.